Jenburkt Pharmaceuticals Limited (BOM:524731)

Market Cap	5.11B +16.4%
Revenue (ttm)	1.69B +11.2%
Net Income	347.36M +8.3%
EPS	78.71 +8.3%
Shares Out	4.41M
PE Ratio	14.72
Forward PE	n/a
Dividend	20.70 (1.79%)
Ex-Dividend Date	Aug 28, 2026

Volume	2,706
Open	1,179.35
Previous Close	1,171.40
Day's Range	1,152.00 - 1,179.50
52-Week Range	944.00 - 1,410.00
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, EC...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 779
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524731

Financial Performance

In fiscal year 2026, Jenburkt Pharmaceuticals's revenue was 1.69 billion, an increase of 11.24% compared to the previous year's 1.52 billion. Earnings were 347.36 million, an increase of 8.34%.